Enzalutamide in Metastatic Castration Resistant Prostate Cancer
Shevach J, Marcellino B, Oh W, Tsao C. Enzalutamide in Metastatic Castration Resistant Prostate Cancer. 2016, 157-169. DOI: 10.1007/978-3-319-31341-2_10.Peer-Reviewed Original ResearchMetastatic castration resistant prostate cancerCastration resistant prostate cancerResistant prostate cancerProstate cancerAndrogen receptor signaling inhibitorsRandomized phase III studyDefinitive survival benefitInduce tumor deathLethal disease phenotypeProstate cancer growthPhase III studyAndrogen-signaling pathwayTreatment of patientsDevelopment of novel treatmentsEnzalutamide therapyAndrogen deprivationIII studiesSurvival benefitPreclinical modelsClinical efficacySafety profileEnzalutamideTumor deathDisease progressionCancer growth
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply